Paraguay Integral Analysis: Full Review Pathway and Article 9 Timelines

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

  1. Article 8, inc. b provides that products which do not meet the conditions of the simplified registration procedure are subject to the Integral Analysis (análisis integral), in which DINAVISA evaluates all items of Article 6. This is the default full-review pathway for any product without qualifying foreign approval.
  2. Article 9 sets the statutory evaluation timeframes: 45 working days for the simplified procedure and 120 working days for the integral analysis.
  3. The deficiency correction timeframes are the same on both pathways: inconsistencies or defects must be remedied within 60 working days; where the reply introduces new information not previously covered and problems arise again, a further 30 working days are granted; if the deadline expires or the technical evaluation is unsatisfactory, the application is denied.
  4. The integral analysis likewise applies to domestically produced Class II, III and IV devices: domestic products do not fall within the two import sub-pathways of Article 8, and their review follows the full evaluation model under the domestic product list of Article 6.

2. Legal basis

RegulationReferenceDateProvisions
Resolution on market authorization requirements for medical devicesResolución DINAVISA N° 226/20242024-08-27; Article 36: entered into force 2024-09-16Article 8 inc. b; Article 9
Operational instructions and guide for submitting applicationsInstructivo ITR–DGRS-002, Versión 022024-09-09Page 10, integral analysis process flow

The integral analysis is described in the resolution and given its own process flow on page 10 of the operational instructions, which is the practical reference for assembling and sequencing the submission. Because the review covers all of Article 6, the flow distinguishes the stages at which each category of document is examined, and applicants who follow the flow when building the file tend to avoid the most common cause of correction rounds, which is documents that are complete but assembled in an order or form the reviewer cannot easily verify.

The correction mechanics deserve equal attention to the evaluation itself. On both pathways, the 60 working day window opens with a notification of inconsistencies or defects, and the clock is unforgiving: an incomplete or evasive reply that satisfies part of the findings but leaves others open simply defers the decision, and where the reply itself introduces new information not previously covered, a second window of 30 working days opens with the same terminal consequences. The resolution grants no third round, so the file that reaches DINAVISA after the first correction is, in practical terms, the last version of the case. Institutions that keep a version-controlled record of every deficiency, every reply and every document version can reconstruct the history of the application at renewal or inspection time, which is also when the quality of that record pays off.

3. Expert insights

Insight one: 120 working days is the official evaluation timeframe, not the project timeline. Article 9 constrains the evaluation activity of DINAVISA only; it does not include the time the company spends preparing materials, translating, certifying or answering deficiencies. Converting 120 working days directly into four months to the certificate underestimates the real timeline, because correction rounds of 60 and 30 working days stack on top of the evaluation clock. Any timeline judgment beyond these statutory timeframes should be treated as a practical estimate, and no specific number of days should be promised externally, since the total depends on factors outside the resolution: readiness of the manufacturer, speed of notarization and the number of correction rounds actually needed.

Insight two: the essence of the integral analysis is a point-by-point pass through Article 6. Where the simplified procedure evaluates only items b, c, d, g and h, the integral analysis covers everything, including a (evidence of the quality management system), e (finished product quality control certificate or notified body conformity certificate) and f (stability studies). This means that under the integral analysis pathway, the completeness of the technical documentation becomes the decisive variable, not a formality check. Projects that treat the file as a formality, assembling it late or from fragmented sources, pay for that in repeated correction rounds and, ultimately, in denial risk.

Insight three: the split between domestic and imported products occurs at a different point. The two sub-pathways of Article 8 apply only to imported products. Domestic Class II, III and IV products submit under the domestic product list of Article 6 (items a to f, with no free sale certificate requirement) and do not enter the simplified versus integral analysis dichotomy. When planning a multi-country supply chain, the choice of manufacturing origin changes the structure of the regulatory pathway: an origin inside Paraguay removes the free sale certificate requirement and the import sub-pathway logic, but it also means the quality system and stability evidence bear the full weight of the review.

4. Practical recommendations

  1. Model the project schedule in three segments: official evaluation timeframe, plus correction rounds, plus front-end preparation. Do not equate the statutory timeframe with the total project cycle, and present internal plans in the same three-segment form so that slippage is visible early.
  2. Under the integral analysis pathway, prioritize items a, e and f of Article 6, namely the quality management system evidence, the finished product quality control certificate and the stability studies; this is the key difference from the simplified pathway and the most common source of gaps.
  3. Answer deficiencies in one complete round to avoid triggering the second 30-working-day correction window, which only opens when the reply itself introduces new information.
  4. For products with multiple manufacturing sites, evaluate the impact of the site choice on the pathway and the document list before fixing the supply chain, including the loss or gain of the free sale certificate requirement.

5. Verification checklist

  • □ Determination completed of whether the product falls under the simplified procedure or the integral analysis
  • □ Dossier prepared against all items of Article 6 (integral analysis pathway), with items a, e and f prioritized
  • □ Schedule model distinguishes the official evaluation timeframe from the total project cycle
  • □ Deficiency replies internally reviewed for completeness in a single round
  • □ Pathway differences assessed for multi-site manufacturing scenarios before the supply chain is fixed

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support for manufacturers, importers and authorized representatives in Paraguay, covering pathway strategy, technical dossier preparation and deficiency management for the integral analysis. Contact: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail